Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, placebo-controlled, proof of concept, antipruritic study of the neurokinin-1 receptor antagonist VLY-686 in subjects with treatment-resistant pruritus associated with atopic dermatitis.

Trial Profile

A randomized, double-blind, placebo-controlled, proof of concept, antipruritic study of the neurokinin-1 receptor antagonist VLY-686 in subjects with treatment-resistant pruritus associated with atopic dermatitis.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tradipitant (Primary)
  • Indications Pruritus
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Vanda Pharmaceuticals
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 04 Mar 2015 Primary endpoint has not been met (efficacy of tradipitant [VLY-686] on reducing chronic pruritus using Visual Analog Scale (VAS)), according to a Vanda Pharmaceuticals media release.
    • 04 Mar 2015 Top-line results published in a Vanda Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top